secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001558370-24-003887
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics reports FY2023 net loss $14.3M ($3.95/share); cash $21.6M; IND cleared for APR-1051
--------------------------------------------------------------------------------

- Cash and equivalents $21.6M at Dec 31, 2023; combined with $16M Mar 2024 private placement funds into Q3 2025.
- Net loss FY2023 $14.3M ($3.95/basic share) vs $112.7M in FY2022 which included $76M acquired IPR&D charge.
- ATRN-119 Phase 1/2a dose escalation on track for 4Q 2024 completion; initial efficacy data expected H2 2024.
- FDA cleared IND for APR-1051 (WEE1 inhibitor); Phase 1 ACESOT-1051 trial to start H1 2024.
- Operating loss $15.5M in FY2023 vs $113.4M in FY2022; R&D expenses fell to $7.6M from $16.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837024003887/0001558370-24-003887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837024003887/apre-20240326x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-003887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer